In view of the potential link between platelet and migraine, we perform a meta-analysis to evaluate the efficacy of the platelet P2Y12 inhibitor in the treatment of migraine and prevention of the occurrence and reduction of the number of new-onset migraine headache (MHA) following ASDC. Here, P2RY12 is linked to migraine disorder.